Second-line combination chemotherapy with docetaxel and nedaplatin for metastatic or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus cisplatin

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Esophagus

• Publication date

  2011-06-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10388-011-0277-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Associations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients.

  2011cited by this paper
• Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study

  2010cited by this paper
• Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity

  2009cited by this paper
• Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.

  2009cited by this paper
• Second-Line Combination Chemotherapy with Docetaxel and Nedaplatin for Cisplatin-Pretreated Refractory Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

  2009cited by this paper
• Comparison of an inflammation‐based prognostic score (GPS) with performance status (ECOG‐ps) in patients receiving palliative chemotherapy for gastroesophageal cancer

  2008cited by this paper
• Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer

  2007cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.

  2006cited by this paper
• Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation

  2006influential reference
• Docetaxel for treatment of solid tumours: a systematic review of clinical data.

  2005cited by this paper
• A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer

  2005cited by this paper
• The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

  2004cited by this paper
• A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.

  2004influential reference
• Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

  2004cited by this paper
• Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy.

  2004cited by this paper
• EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

  2003cited by this paper
• Esophageal cancer.

  2003cited by this paper
• Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease

  2003cited by this paper
• Phase II Trial of Docetaxel Chemotherapy in Patients with Incurable Adenocarcinoma of the Esophagus

  2002influential reference
• Treatment Outcomes of Resected Esophageal Cancer

  2002cited by this paper
• Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.

  2001cited by this paper
• Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407).

  2001cited by this paper
• Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?

  1999cited by this paper
• Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.

  1999cited by this paper
• Chemotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus

  1998cited by this paper
• Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

  1998cited by this paper
• Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

  1997cited by this paper
• A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

  1996cited by this paper
• [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group].

  1992cited by this paper
• Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial.

  1992influential reference
• A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus

  1991cited by this paper
• Cancer Chemotherapy by Infusion

  1987cited by this paper
• Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

  1986cited by this paper
• SYNTHESIS OF (GLYCOLATO-O,O′)DIAMMINEPLATINUM(II) AND ITS RELATED COMPLEXES

  1986cited by this paper
• Gastrointestinal Cancer Targeted Therapies for Esophageal Cancer Introduction

  year unknowncited by this paper

• Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma

  2016cites this paper
• 切除不能進行食道癌放射線療法症例における Glasgow Prognostic Score（GPS）による予後評価

  2014cites this paper